BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
News|Articles|January 27, 2015
SGS Expands West Chester Facility and Increases Protein Structural Analysis Services
Author(s)Pharmaceutical Technology Editors
The company has installed and validated new instruments for structural analysis of proteins.
Advertisement
SGS Life Science Services, a provider of pharmaceutical analytical and bioanalytical solutions, has completed the expansion its facility in West Chester, PA. The company has installed and validated new instruments for structural analysis of proteins, which includes analytical ultra centrifugation (AUC) to assess protein aggregation, size exclusion chromatography with multi-angle laser light scattering for molecular weight measurements, and Fourier transform infrared spectroscopy (FTIR) to examine protein secondary structure.
The addition of these new services complements existing services at the West Chester facility. It now offers capabilities similar to SGS’ Wokingham site in the United Kingdom, including investigation of lot-to-lot variations, biosimilar comparability, and shipment excursion studies to monitor the stability and sensitivity of biological molecules under various storage conditions.
Source:
Advertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Sanjay Konagurthu, PhD, senior director of Science and Innovation at Thermo Fisher Scientific, explains what teams need to do to ensure the usefulness of AI and what strides have been made with AI in regulatory submissions.
Pauric Bannigan, Intrepid Labs, explains where AI speeds formulation decisions, why data is the bottleneck, and how active learning trains models with far less data.
The new initiative aims to apply traceable AI and science to expand care worldwide by translating discovery into tools that accelerate drug development.
Sanjay Konagurthu, PhD, senior director, Science and Innovation at Thermo Fisher Scientific, provides an update on the progress of AI and machine learning used in drug delivery.
Stephanie Johnson, Pfizer, explains how off-platform triggers, single-owner risk registers, and traceable prior knowledge keep protein formulation programs on track.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Leaders Weigh in On AI's Measurable Results In 2026
2
Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight
3
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
4
Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities
5